GT Biopharma, Inc. GTBP introduced Monday that it has efficiently accomplished dosing in Cohort 1 and began dosing in Cohort 2 of its Part 1 dose escalation trial for GTB-3650. The remedy is a second-generation TriKE therapeutic focusing on relapsed or refractory CD33-expressing hematologic malignancies.
GT Biopharma makes a speciality of immuno-oncology therapies utilizing its proprietary TriKE NK cell engager platform and holds an unique international license with the College of Minnesota for its improvement and commercialization.
No security or tolerability points had been noticed in Cohort 1, permitting development to the subsequent cohort, the corporate stated.
Early biomarker evaluation from Cohort 1 sufferers signifies elevated immunologic exercise, suggesting activation and growth of pure killer (NK) cells.
The trial, which can embrace as much as 14 sufferers throughout seven cohorts, entails two-week dosing blocks over a four-month interval and can consider security, pharmacokinetics, pharmacodynamics, NK cell growth, and scientific exercise.
The corporate stated that it’ll launch detailed ends in 2025.
In January, the corporate had initiated affected person dosing with GTB-3650 within the Part 1 trial to judge the potential in sufferers with hematological malignancies.
Value Motion: GTBP inventory traded greater by 0.90% to $2.26 premarket on the final test on Monday.
Learn Subsequent:
Picture by Aunt Spray through Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
